Navigation Links
Discovery Labs Reports Third Quarter 2013 Financial Results
Date:11/12/2013

WARRINGTON, Pa., Nov. 12, 2013 /PRNewswire/ -- Discovery Laboratories, Inc. (Nasdaq: DSCO), a specialty biotechnology company dedicated to advancing a new standard in respiratory critical care, today announced financial results for the third quarter ended September 30, 2013, as well as recent business updates. The Company will host a conference call Wednesday morning, November 13, 2013 at 10:00 AM ET.  Conference call details are below.

Key updates include:

  • SURFAXIN®:  On October 4, 2013, the U.S. Food and Drug Administration (FDA) agreed to the Company's updated product specifications for SURFAXIN (lucinactant) Intratracheal Suspension.  SURFAXIN is the first FDA-approved synthetic, peptide containing surfactant available for the prevention of respiratory distress syndrome (RDS) in premature infants and the only approved alternative to animal-derived surfactants currently available today in the U.S. On November 8, 2013, the Company announced that it has initiated the commercial introduction of SURFAXIN in the U.S.
  • AEROSURF®:  In October 2013, the Company submitted an investigational new drug (IND) application to the FDA to initiate its AEROSURF phase 2 clinical program.  The FDA has completed its review and cleared the IND, and the Company can now proceed with its phase 2 clinical program.  AEROSURF is a novel investigational drug-device combination product being developed to deliver the Company's KL4 surfactant in aerosolized form to premature infants with RDS.  AEROSURF could potentially provide neonatologists with the ability to avoid invasive procedures and thereby enable the treatment of a significantly greater number of premature infants who could benefit from surfactant therapy and currently are not treated.  The Company anticipates results from the first phase of its AEROS
    '/>"/>

  • SOURCE Discovery Laboratories, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9

    Related biology technology :

    1. Novartis: Layoffs as a Sign of Productivity Crisis in R&D; The CBCD Offers New Technology to Aid in Drug Discovery
    2. Discovery Labs to Host Conference Call to Discuss Third Quarter 2013 Results on Wednesday, November 13, 2013
    3. Global Aptamers Market Technology Trend Analysis Market Report 2013-2018: Therapeutics, Diagnostics, Biosensors, Biomarker/Drug Discovery & Applications
    4. Discovery Labs Announces Completion of $50 Million Public Offering
    5. Discovery Labs Prices $50 Million Public Offering of Common Stock
    6. Discovery Labs Announces Proposed Public Offering of Common Stock
    7. Productivity Crisis in Pharmaceutical Industry Increases Drug Prices; The CBCD Offers New Technology to Aid in Drug Discovery
    8. Vet-Stem, Inc. Founder and CEO Presents at TargetMeeting’s 3rd World Drug Discovery Online Conference
    9. Drug Discovery Using Natural Products - Optimization Studies of Inhibitors of Glucan Synthesis as Anti-Fungal Agents, New Life Science Webinar Hosted by Xtalks
    10. Global Biosimulation Technology Market (For Drug Discovery & Development) (2012 - 2017)
    11. Discovery Meets Recovery in New Cedars-Sinai’s Advanced Health Sciences Pavilion Designed by HOK
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:1/22/2015)... PALO ALTO, Calif. , Jan. 22. 2015  Varian Medical ... equipment and software, has been honored for its commitment to ... most sustainable companies. Varian is the highest ranked healthcare equipment ... ranking, announced today during the World Economic Forum at ...
    (Date:1/22/2015)... 22, 2015  Derma Sciences, Inc. (Nasdaq: ... advanced wound care, announces that AMNIOEXCEL® and AMNIOMATRIX®, ... added to the Premier, Inc. Regenerative Skin Grafting ... the AMNIOEXCEL® and AMNIOMATRIX® product lines, which continue ...
    (Date:12/24/2014)...  United Therapeutics Corporation (NASDAQ: UTHR ) announced ... has submitted a pre-market approval application to the U.S. ... Medtronic,s SynchroMed ® II implantable drug infusion system ... Therapeutics, Remodulin ® (treprostinil) Injection delivered intravenously to ...
    (Date:12/24/2014)... Dec. 24, 2014  Vermillion, Inc. (Nasdaq:   VRML), ... announced today that the Company closed its previously ... Management, Jack W. Schuler , Birchview Fund ... $10.5 million, before offering expenses.  The proceeds will ...
    Breaking Biology Technology:Varian Honored Among World's 100 Most Sustainable Corporations 2Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 2Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 3Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 4Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 5United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 3United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 4Vermillion Announces Closing of Equity Financing 2Vermillion Announces Closing of Equity Financing 3
    ... Calif., March 12 ,Exelixis, Inc. (Nasdaq: EXEL ) ... executive officer of Exelixis, will present at the,Cowen and ... / 1:00 p.m.,PT on Monday, March 17, 2008. Dr. ... corporate strategy., The presentation will be webcast and ...
    ... DIEGO, March 12 Biomatrica, the leader in ... a reagent that enhances PCR and RT-PCR performance ... amplification of genomic,DNA or RNA templates., PCRboost ... that are,traditionally difficult to amplify and present in ...
    ... 12 Oncolys BioPharma,Inc. (Tokyo, Japan) and Tacere ... they have entered into a strategic alliance and,license ... interference (RNAi)-based Hepatitis C virus (HCV) compound, TT-033,code-named ... the,strategic alliance entered into by Tacere and Oncolys ...
    Cached Biology Technology:Biomatrica's PCRboost(TM) Enables 5-Fold Improvement in Amplification of Difficult Samples 2Oncolys BioPharma and Tacere Therapeutics Sign Strategic Alliance and License Agreement to Develop and Commercialize RNAi Hepatitis C Drug 2Oncolys BioPharma and Tacere Therapeutics Sign Strategic Alliance and License Agreement to Develop and Commercialize RNAi Hepatitis C Drug 3
    (Date:1/22/2015)... Jan. 15, 2015  BellBrook Labs, a leader in ... the launch of a TR-FRET (time resolved Forster ... UDP Assay, a high throughput screening assay for ... will allow for sensitive detection of hundreds of ...
    (Date:1/22/2015)... , Jan. 21, 2015  Analyst Report Issued by Small Cap ... report showed that planet-wide, transactions at merchants on the leading ... total number of credit, debit, and prepaid cards reached 6.54 ... victims of fraudulent card usage in 2012, and credit and ...
    (Date:1/22/2015)... CHARLOTTE, N.C. , Jan. 22, 2015 Infinisource has ... introduction of the G2 model. The G2 sets a higher ... company,s iSolved human capital management solution. With plug-and-play installation, touch ... G2 time clock provides a robust time collection solution for ...
    Breaking Biology News(10 mins):BellBrook Labs Launches a High Throughput Screening Assay for Glycosyltransferases with TR-FRET Readout 2$4.80 Near Term Price Target with "Buy" given by CapRock Research for NXT-ID, Inc. (NASDAQ: NXTD) issued by Small Cap IR 2Infinisource's NXG series sets new time clock standard 2
    ... Ridge Associated Universities (ORAU), a consortium of 98 Ph.D.-granting ... sciences in the University of Delaware,s College of Earth, ... Junior Faculty Enhancement Award. The competitive award, which ... from the faculty member,s university, is intended to enrich ...
    ... the National Oceanography Centre (NOC) joins forces with the ... Porcupine Abyssal Plain sustained observatory (PAP-SO), the longest multidisciplinary ... advance scientific understanding of the ocean and improve climate ... North Atlantic off the Irish continental margin, where the ...
    ... PITTSBURGH, May 25 A two-year, $12 million contract ... Transition (OTT) will jumpstart human trials of three innovative ... with healthy, functional tissues, announced officials of the University ... today at the Institute,s Second Annual Open Session, Soldiers ...
    Cached Biology News:University of Delaware professor wins Powe Award from Oak Ridge Associated Universities 2University of Delaware professor wins Powe Award from Oak Ridge Associated Universities 3Met Office and NOC enhance ocean observatory 2Pitt gets $12 million DoD contract for regenerative medicine treatment trials 2
    Request Info...
    Prepared with distilled water. Yeast extract solution is autolyzed at 150 g/L....
    Streptomycin sulfate an aminoglycoside used for bacterial selection binds to the small ribosomal subunit and interferes with protein biosynthesis.21H39N7O12)2x3H2SO4Formula weight:...
    ...
    Biology Products: